Skip to main content

Table 3 Treatment duration and maintenance treatment duration

From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Treatment duration N = 30
Months, median (95% CI) 7.9 (6.3–11.4)
Cycles, median (range) 11 (3–32)
Patients on treatment >6 months, n (%) 21 (70)
Patients on treatment >1 year, n (%) 7 (23.3)
Maintenance treatment duration N = 24
Months, median (95% CI) 6.9 (3.0–9.8)
Patients on maintenance treatment >6 months, n (%) 11 (36.7)
Patients on maintenance treatment >1 year, n (%) 2 (6.7)